Implantica stock
IMP-A-SDB.STSTOImplantica AG, HealthcareISIN SE0014855029
50Score 50 out of 100, Neutral
Price and trend
86 / 100
Price history
+13% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 24% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 9.0% below its 52-week high. Largest decline in 6 years: 91% (January 2021 to May 2023).
Chart figures for advanced users
- SMA 50$6.41
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.53
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.89
- The lowest closing price of the last twelve months.
- Resistance$7.54
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Implantica AG belongs to the Medical (Devices) industry (Liechtenstein) and, with a market value of $400.4M, is number 84 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.34M (up 9.1% year on year) and a loss of $22.16M.
- MEQIRI Score 50 out of 100 (Neutral): rank 375 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 69.3% a year since 2020, Medical (Devices) median 13.8%.Growth 70
- More cash than debtCash $46.37M, financial debt $212.22K.Stability 57
Weaknesses
- Loss-makingLoss of $21.81M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$16.35M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 50% a year over the last 12 months.Stability 57
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 49 to 50.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 24.7% on the twelve months before. Revenue turned from negative at the start of the period to positive ($2.34M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −41%, operating −929%, net −947%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 19 Nov 2026in 6 days
- Last reported
- 21 Aug 2026EPS reported −0.67 (expected −0.8)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −0.29+1.1%
- Revenue
- $3.27M−1.1%
- Earnings per share
- −0.36+1.1%
- Revenue
- $9.8M−1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Implantica
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 50
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- CellaVisionCEVI.ST $483.11M80
- Metall ZugMETN.SW $460.29M40
- Revenio GroupREG1V.HE $419.17M47
- NeuroPaceNPCE $412.58M32
- CerusCERS $391.79M33
- StratecSBS.DE $360.32M52
- Treace Medical ConceptsTMCI $350.09M48
- CapsoVisionCV $333.63M38
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729, $1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Weak
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.